We also rely on our contract manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials.
Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: ld negatively impact our business. ● If our partners do not satisfy their obligations under our agreements with them, …
ld negatively impact our business. ● If our partners do not satisfy their obligations under our agreements with them, or if they terminate our partnerships with them, we may not be able to develop or…
Reciprocal relationship from MLTX graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to ex…
Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain not…
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from PTGX graph: s and Other Commitments In the normal course of business, we enter into agreements with contract service providers t…
s and Other Commitments In the normal course of business, we enter into agreements with contract service providers to assist in the performance of our research and development activities and clinical…
Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PTGX graph: The Company has earned a total of $ 3…
Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain not…
de whole with respect to a future bank failure, account holders’ access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in t…
ve date of the contract through December 31, 2024. The Company determined that the Takeda Collaboration Agreement met the definition of a collaborative arrangement under ASC Topic 808. Both parties…
Item 1A, “ Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC, before making an investment decisio…
Protagonist Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PTGX-DEBT-11935
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-12-31.
PTGX-DEBT-11934
Warrants outstanding: 1500000
90%
xbrl warrant detail from xbrl 2026-03-31.
PTGX-DEBT
Debt stack $9.8M
90%
Market cache reports total debt of $9.8M.
Protagonist Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Protagonist Therapeutics, Inc..
Protagonist Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
PTGX-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 325 tracked holders.
Protagonist Therapeutics, Inc. Extended Supply Chain Network
